ReviewEuropean journal of cancer (Oxford, England : 1990)2021
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Review in European journal of cancer (Oxford, England : 1990), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.International immunopharmacology · 2022Pooled it
- Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment.Human vaccines & immunotherapeutics · 2025Article
- Article
- Article
- Global, regional, and national burden of esophageal cancer: a systematic analysis of the Global Burden of Disease Study 2021.Biomarker research · 2025Article
- Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial.Therapeutic advances in medical oncology · 2025Article
- Humoral Response to SARS-CoV-2 Vaccine-Boost in Cancer Patients: A Case Series from a Southern European Cancer Center.Vaccines · 2024Article
- How does geographical diversity shape vaccine efficacy?Clinical and experimental vaccine research · 2024Review
- Article
- Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain.Nature communications · 2024Article
- Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care.Viruses · 2024Review
- Article
- Article
- Single-Cell Transcriptomics Reveals Pre-existing COVID-19 Vulnerability Factors in Lung Cancer Patients.Molecular cancer research : MCR · 2024Article
- Clinical characteristics and prognostic factors of COVID-19 infection among cancer patients during the December 2022 - February 2023 Omicron variant outbreak.Frontiers in medicine · 2024Article
- Coronavirus Anatomy and Its Analytical Approaches for Targeting COVID-19.Advances in experimental medicine and biology · 2024Review
- Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.Human vaccines & immunotherapeutics · 2023Article
- Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.JMIR public health and surveillance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEfficacy and safety data of COVID-19 vaccines among cancer populations have been limited; however, preliminary data from recent studies have emerged regarding their immunogenicity and safety in this population. In this review, we examined current peer-reviewed publications containing serological and safety data after COVID-19 vaccination of patients with cancer.
methodsThis analysis examined 21 studies with a total of 5012 patients with cancer, of which 2676 (53%) had haematological malignancies, 2309 (46%) had solid cancers and 739 were healthy controls. Serological responses by anti-SARS-CoV-2 spike protein S1/S2 immunoglobulin G antibody levels and post-vaccination patient questionnaires regarding vaccine-related side-effects after the first and second dose were collected and analysed.
resultsIn general, a single dose of the COVID-19 vaccine yields weaker and heterogeneous serological responses in both patients with haematological and solid malignancies. On receiving a second dose, serological response rates indicate a substantial increase in seropositivity to the SARS-CoV-2 spike protein in all cancer cohorts, but antibody titres remain reduced in comparison with healthy controls. Furthermore, seroconversion in patients with haematological malignancies was significantly lower than that in patients with solid tumours. COVID-19 vaccines are safe and well-tolerated in patients with cancer based on current data of local and systemic effects.
conclusionTogether, these data support the prioritisation of patients with cancer to receive their first and second doses to minimise the risk of COVID-19 infection and severe complications in this vulnerable population. Additional prophylactic measures must be considered for high-risk patients where current vaccination programs may not mount sufficient protection against SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.